Multiplex Assay Kit for Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array)

TN-C; HXB; TN; GMEM; JI; Myotendinous antigen; Neuronectin; GP 150-225; Cytotactin; Hexabrachion; Glioma-associated-extracellular matrix antigen

Specificity

This assay has high sensitivity and excellent specificity for detection of Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array).
No significant cross-reactivity or interference between Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-99 92
EDTA plasma(n=5) 82-91 86
heparin plasma(n=5) 78-105 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-97% 95-102% 84-102% 80-99%
EDTA plasma(n=5) 80-99% 83-91% 81-104% 80-99%
heparin plasma(n=5) 96-103% 92-101% 98-105% 84-96%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity

Assay procedure summary

1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Medical Principles and Practice An investigation of tenascin-C levels in rheumatic mitral stenosis and their response to percutaneous mitral balloon valvuloplasty Pubmed: 22889719
Tumor Biology Clinical significance of serum tenascin-c levels in epithelial ovarian cancer Springer: Source
Tumor Biology Clinical significance of serum tenascin-C levels in breast cancer Springer: Source
BioFactors Tenascin-C is increased in atherothrombotic stroke patients and has an anti-inflammatory effect in the human carotid artery. Pubmed:24823872
Connective Tissue Research Metabolic and cytoprotective effects of in vivo peri-patellar hyaluronic acid injections in cultured tenocytes Pubmed:25333747
K Role of Tenascin-C in the differential diagnosis of small round blue cell tumors Index.Php: Sdutfd
Life Sci A new predictor of mortality in hemodialysis patients; Tenascin-C PubMed: 26390818
Heart Research Biomarkers Score for Patients with Mitral Stenosis: A useful conjunction with Wilkins’s Score for Early Intervention Heartresearchopenjournal: Hroj5
Araştırmalar / Researches Pankreas Adenokarsinomunda Serum Tenascin-C Düzeyi Potansiyel Bir Biyobelirteç Midir? Cpdf:5C21620161255
Archives of Dermatological Research Increased tenascin C and DKK1 in vitiligo: possible role of fibroblasts in acral and non-acral disease Pubmed:29605863
Methods in Cell Biology How to detect and purify tenascin-C Pubmed:29310788
Scientific Reports Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion Pubmed: 31358880
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB975Hu02 Recombinant Tenascin C (TNC) Positive Control; Immunogen; SDS-PAGE; WB.
RPB975Hu01 Recombinant Tenascin C (TNC) Positive Control; Immunogen; SDS-PAGE; WB.
PAB975Hu01 Polyclonal Antibody to Tenascin C (TNC) IHC
PAB975Hu02 Polyclonal Antibody to Tenascin C (TNC) WB; IHC; ICC; IP.
LAB975Hu71 Biotin-Linked Polyclonal Antibody to Tenascin C (TNC) WB; IHC; ICC.
MAB975Hu22 Monoclonal Antibody to Tenascin C (TNC) IHC
MAB975Hu21 Monoclonal Antibody to Tenascin C (TNC) IHC
MAB975Hu23 Monoclonal Antibody to Tenascin C (TNC) IHC
MAB975Hu24 Monoclonal Antibody to Tenascin C (TNC) IHC
SEB975Hu ELISA Kit for Tenascin C (TNC) Enzyme-linked immunosorbent assay for Antigen Detection.
CMB975Hu Multiplex Assay Kit for Tenascin C (TNC) ,etc. by CBA (Cytometric Bead Array) FLIA Kit for Antigen Detection.
LMB975Hu Multiplex Assay Kit for Tenascin C (TNC) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.